Project Grant HT94252510397
Award Date
5/15/25
Completion Date
5/14/26
Dollars Obligated
$179K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $168,042 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports in vivo targeting research related to TFE3 dimerization partners in translocation renal cell carcinoma at Brigham & Women's Hospital Inc. in Boston, Massachusetts. The award will fund advanced biomedical research focused on developing innovative diagnostic and therapeutic approaches for this specific type of kidney cancer, which is...
This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $130,698 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support the development of the first targeted therapy for translocation renal cell carcinoma from August 15, 2022 to August 14, 2023. As the parent organization of the awardee, Partners Healthcare System Incorporated will oversee delivery of this innovative medical research effort to develop new...
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $648,276 Project Grant under the Military Medical Research and Development program. The three-year award will fund research from September 2022 to September 2025 to target TFEB and TFE3 in renal tumorigenesis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $660,937 project grant to Brigham & Women's Hospital Inc. on September 30, 2023, to support the "Identification of Novel Therapeutic Strategies for Chromophobe RCC" research project. This 3-year grant will fund basic and applied biomedical research to investigate new treatment approaches for chromophobe renal cell carcinoma, a rare form of kidney cancer. Brigham & Women's...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $169,372.00 to Brigham & Women's Hospital Inc. to support research on "ENGINEERING ANTAGOMIR NANODISCS TO REPROGRAM RCC-ASSOCIATED FIBROBLASTS". The award period runs from July 1, 2024 to June 30, 2026. The research aims to develop novel therapeutic approaches targeting renal cell carcinoma (RCC) by reprogramming the associated...
The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...
This federal Project Grant award of $855,709.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Brigham & Women's Hospital Inc. to target mitochondrial metabolism in Tuberous Sclerosis Complex. The 3-year project, running from September 1, 2023 to August 31, 2026, aims to transform healthcare for Service Members and the American public through innovative and impactful biomedical research on this rare...